2024-519327-20-00招募中1 期
A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer2022-502125-17-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14
招募中
2 期
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors2022-503066-74-00Bioinvent International AB84
招募中
2 期
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
招募中
1 期
A study to test how well different doses of BI 3804379 are tolerated by healthy people2024-513549-36-01Boehringer Ingelheim International GmbH106
招募中
2 期
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema2024-520384-14-00Boehringer Ingelheim International GmbH193